Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe CRSwNP patients
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Management of severe chronic rhinosinusitis with nasal polyps (CRSwNP) has changed significantly in recent years, with different treatments now available including biologics and endoscopic sinus surgery (ESS), although there are still few comparative studies. We aimed to compare 1-year outcomes of patients with severe CRSwNP treated with dupilumab or ESS plus intranasal corticosteroids (INCS). METHODS: In this retrospective, real-life, observational, cohort study, we enrolled 101 patients with severe CRSwNP who were treated with INCS and either ESS (n = 49) or dupilumab (n = 52). The following outcomes were considered: nasal polyp score (NPS), Sino Nasal Outcome Test-22 (SNOT-22), visual analogue scale (VAS) for specific symptoms, Sniffin' Sticks identification test (SSIT), need for oral corticosteroids (OCS) and local eosinophilia detected by nasal cytology. RESULTS: ΔNPS was significantly higher in the surgery group up to 12 months when the difference with dupilumab group was no longer significant (ΔNPS: 4 vs. 4.1). ΔVAS rhinorrhoea, ΔVAS smell and ΔSNOT-22 were significantly higher in the dupilumab group at 12 months (p < .05). SSIT scores were significantly better in the dupilumab group starting from the first month of follow-up (p < .05). In the dupilumab group, only 6.1% of patients had detectable local eosinophilia compared to 57% in the surgery group alongside with a lower need for OCS (16.3% vs. 61%). CONCLUSIONS: Both dupilumab and ESS were effective in improving outcomes in patients with severe CRSwNP over 12 months. Nevertheless, patients treated with dupilumab had greater improvement in terms of SNOT-22, VAS rhinorrhoea, VAS smell and SSIT scores, with better control of local inflammation and less need for OCS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Comparative real‐world outcomes of dupilumab versus endoscopic sinus surgery in the treatment of severe <scp>CRSwNP</scp> patients
- Date Crossref
- 06/05/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Agostino Gemelli University Polyclinic pays non établi dans la noticeÉtablissement de santé
-
Università Cattolica del Sacro Cuore pays non établi dans la noticeUniversité ou école supérieure
-
Ospedale di Rivoli pays non établi dans la noticeÉtablissement de santé
-
Unit of Otorhinolaryngology and Head‐Neck Surgery “A. Gemelli” Hospital Foundation IRCCS Rome Italy pays non établi dans la noticeÉtablissement de santé
-
Department of Head‐Neck and Sensory Organs Catholic University of Sacred Heart Rome Italy pays non établi dans la noticeUniversité ou école supérieure
-
ENT Department Rivoli Hospital pays non établi dans la noticeÉtablissement de santé
-
Unit of Radiology “A. Gemelli” University Hospital Foundation IRCCS Rome Italy pays non établi dans la noticeUniversité ou école supérieure
Agostino Gemelli University Polyclinic, Università Cattolica del Sacro Cuore et Ospedale di Rivoli, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.